COGT

Cogent Biosciences, Inc.

Price Chart

Latest Quote

$34.54

+0.87 (+2.58%)

Current Price

Previous Close	$33.67
Open	$34.19
Day High	$34.99
Day Low	$33.81
Volume	4,894,981

Fetched: 2026-06-20T00:04:15

Stock Information

Shares Outstanding	170.87M
Total Debt	$238.65M
Cash Equivalents	$866.38M
Net Income	$-354.30M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$5.90B
EPS (TTM)	$-2.17
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$5.09B
Income	$-354.30M
Book/sh	$3.18
Cash/sh	$5.07
Employees	258

Financial Ratios

Quick Ratio	14.94
Current Ratio	15.14
Debt/Eq	39.27

Returns & Margins

ROA	-38.13%
ROE	-85.72%

Ownership

Insider Ownership	0.43%
Institutional Ownership	112.16%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-36.14
P/B	10.87

Analyst Data

Recommendation	strong_buy
Target Price	$54.25

Technical Indicators

SMA20	$33.12
SMA50	$34.55
SMA200	$31.09
RSI	47.88
ATR	1.4585

Shares Float	160.86M
Short Float	6.78%
Short Ratio	6.21
Volatility	0.35
Rel Volume	1.97

Performance History

Week	+5.89%
Month	+10.53%
Quarter	-0.20%
6 Months	-13.63%
YTD	-0.58%
Year	+353.28%
3 Years	+169.00%
5 Years	+324.85%
10 Years	-22.28%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$34.54	4,898,300
2026-06-17	$33.67	2,068,000
2026-06-16	$33.07	1,603,100
2026-06-15	$33.17	1,974,700
2026-06-12	$33.10	1,480,100
2026-06-11	$32.62	1,823,400
2026-06-10	$31.38	2,510,100
2026-06-09	$31.98	3,082,200
2026-06-08	$31.16	1,901,400
2026-06-05	$31.02	1,795,000
2026-06-04	$32.79	1,600,100
2026-06-03	$32.26	2,472,800
2026-06-02	$32.76	4,267,100
2026-06-01	$34.81	3,073,900
2026-05-29	$34.96	2,948,700
2026-05-28	$35.38	2,722,900
2026-05-27	$34.51	3,093,400
2026-05-26	$33.94	2,815,400
2026-05-22	$32.67	1,966,900
2026-05-21	$32.58	1,576,700
2026-05-20	$32.92	2,035,200
2026-05-19	$31.25	2,819,100

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

📰 Latest News

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

MT Newswires • 2026-06-12T12:58:31Z

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

Simply Wall St. • 2026-06-10T02:13:01Z

Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?

Insider Monkey • 2026-06-07T16:42:59Z

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter

Motley Fool • 2026-05-31T20:16:27Z

Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback

Simply Wall St. • 2026-05-26T00:18:31Z

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Motley Fool • 2026-05-23T22:40:03Z

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Motley Fool • 2026-05-23T22:33:51Z

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

Motley Fool • 2026-05-18T17:44:01Z

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Motley Fool • 2026-05-18T17:33:34Z

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Motley Fool • 2026-05-17T19:13:24Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$3,062,000	$0	$0	-
Total Expenses	$333,363,000	$275,939,000	$208,130,000	$147,839,000
Other Income Expense	$-7,201,000	$1,992,000	$2,643,000	$3,609,000
Other Non Operating Income Expenses	$-20,000	$1,992,000	$2,643,000	$3,609,000
Net Non Operating Interest Income Expense	$11,627,000	$18,088,000	$13,077,000	$3,989,000
Interest Expense Non Operating	$3,062,000	$0	$0	-
Operating Expense	$333,363,000	$275,939,000	$208,130,000	$147,839,000
General And Administrative Expense	$63,583,000	$43,281,000	$34,375,000	$26,212,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Net Interest Income	$11,627,000	$18,088,000	$13,077,000	$3,989,000
Interest Income	$14,689,000	$18,088,000	$13,077,000	$3,989,000
Normalized Income	$-321,756,000	$-255,859,000	$-192,410,000	$-140,241,000
Net Income From Continuing And Discontinued Operation	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Total Operating Income As Reported	$-333,363,000	$-275,939,000	$-208,130,000	$-147,839,000
Net Income Common Stockholders	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Net Income	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Net Income Including Noncontrolling Interests	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Net Income Continuous Operations	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Pretax Income	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Special Income Charges	$-7,181,000	$0	$0	-
Interest Income Non Operating	$14,689,000	$18,088,000	$13,077,000	$3,989,000
Operating Income	$-333,363,000	$-275,939,000	$-208,130,000	$-147,839,000
Per Share
Diluted EPS	$-2.04	$-2.32	$-2.42	$-2.39
Basic EPS	$-2.04	$-2.32	$-2.42	$-2.39
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-314,111,000	$-251,508,000	$-188,822,000	$-141,961,000
Total Unusual Items	$-7,181,000	$0	$0	-
Total Unusual Items Excluding Goodwill	$-7,181,000	$0	$0	-
Reconciled Depreciation	$4,583,000	$4,351,000	$3,588,000	$5,878,000
EBITDA (Bullshit earnings)	$-321,292,000	$-251,508,000	$-188,822,000	$-141,961,000
EBIT	$-325,875,000	$-255,859,000	$-192,410,000	$-147,839,000
Diluted Average Shares	$160,980,024	$110,461,729	$79,657,942	$58,739,713
Basic Average Shares	$160,980,024	$110,461,729	$79,657,942	$58,739,713
Diluted NI Availto Com Stockholders	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Other Special Charges	$7,181,000	-	-	-
Research And Development	$269,780,000	$232,658,000	$173,755,000	$121,627,000
Selling General And Administration	$63,583,000	$43,281,000	$34,375,000	$26,212,000
Other Gand A	$63,583,000	$43,281,000	$34,375,000	$26,212,000
Gain On Sale Of Ppe	-	-	-	-

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$636,371,000	$256,286,000	$257,802,000	$255,735,000
Total Assets	$937,607,000	$327,898,000	$313,437,000	$300,810,000
Total Non Current Assets	$27,252,000	$31,426,000	$42,666,000	$35,844,000
Other Non Current Assets	$3,717,000	$4,862,000	$4,864,000	$4,745,000
Current Assets	$910,355,000	$296,472,000	$270,771,000	$264,966,000
Other Current Assets	$9,590,000	$9,395,000	$5,061,000	$4,435,000
Cash Cash Equivalents And Short Term Investments	$900,765,000	$287,077,000	$265,710,000	$259,276,000
Cash And Cash Equivalents	$312,012,000	$98,165,000	$53,229,000	$139,886,000
Investmentin Financial Assets	-	$0	$7,460,000	$0
Restricted Cash	-	-	$0	$1,255,000
Prepaid Assets	-	-	-	$4,435,000
Debt
Total Debt	$238,797,000	$17,467,000	$18,853,000	$19,649,000
Long Term Debt And Capital Lease Obligation	$237,250,000	$15,902,000	$17,467,000	$18,226,000
Long Term Debt	$222,895,000	-	-	-
Current Debt And Capital Lease Obligation	$1,547,000	$1,565,000	$1,386,000	$1,423,000
Liabilities
Total Liabilities Net Minority Interest	$301,236,000	$71,612,000	$55,635,000	$45,075,000
Total Non Current Liabilities Net Minority Interest	$237,283,000	$15,902,000	$17,467,000	$18,226,000
Other Non Current Liabilities	$33,000	-	-	-
Current Liabilities	$63,953,000	$55,710,000	$38,168,000	$26,849,000
Other Current Liabilities	$6,745,000	$373,000	$441,000	$2,104,000
Payables And Accrued Expenses	$39,921,000	$41,513,000	$26,467,000	$17,259,000
Payables	$9,504,000	$12,013,000	$10,655,000	$5,842,000
Accounts Payable	$9,504,000	$12,013,000	$10,655,000	$5,842,000
Current Deferred Liabilities	-	-	-	$1,700,000
Equity
Common Stock Equity	$546,978,000	$145,686,000	$197,767,000	$189,905,000
Preferred Stock Equity	$89,393,000	$110,600,000	$60,035,000	$65,830,000
Total Equity Gross Minority Interest	$636,371,000	$256,286,000	$257,802,000	$255,735,000
Stockholders Equity	$636,371,000	$256,286,000	$257,802,000	$255,735,000
Gains Losses Not Affecting Retained Earnings	$355,000	$447,000	$246,000	$-104,000
Other Equity Adjustments	$355,000	$447,000	$246,000	$-104,000
Retained Earnings	$-1,188,420,000	$-859,483,000	$-603,624,000	$-411,214,000
Other
Ordinary Shares Number	$160,980,024	$110,461,729	$86,124,249	$69,893,434
Share Issued	$160,980,024	$110,461,729	$86,124,249	$69,893,434
Tangible Book Value	$546,978,000	$145,686,000	$197,767,000	$189,905,000
Invested Capital	$769,873,000	$145,686,000	$197,767,000	$189,905,000
Working Capital	$846,402,000	$240,762,000	$232,603,000	$238,117,000
Capital Lease Obligations	$15,902,000	$17,467,000	$18,853,000	$19,649,000
Total Capitalization	$859,266,000	$256,286,000	$257,802,000	$255,735,000
Additional Paid In Capital	$1,734,882,000	$1,004,612,000	$801,059,000	$601,153,000
Capital Stock	$89,554,000	$110,710,000	$60,121,000	$65,900,000
Common Stock	$161,000	$110,000	$86,000	$70,000
Preferred Stock	$89,393,000	$110,600,000	$60,035,000	$65,830,000
Long Term Capital Lease Obligation	$14,355,000	$15,902,000	$17,467,000	$18,226,000
Current Capital Lease Obligation	$1,547,000	$1,565,000	$1,386,000	$1,423,000
Pensionand Other Post Retirement Benefit Plans Current	$15,740,000	$12,259,000	$9,874,000	$6,063,000
Current Accrued Expenses	$30,417,000	$29,500,000	$15,812,000	$11,417,000
Net PPE	$23,535,000	$26,564,000	$30,342,000	$31,099,000
Accumulated Depreciation	$-8,679,000	$-6,115,000	$-3,665,000	$-1,401,000
Gross PPE	$32,214,000	$32,679,000	$34,007,000	$32,500,000
Leases	$2,463,000	$2,463,000	$2,438,000	$1,776,000
Construction In Progress	$763,000	$41,000	$27,000	$482,000
Other Properties	$8,847,000	$8,083,000	$7,635,000	$5,507,000
Machinery Furniture Equipment	$2,063,000	$1,995,000	$1,909,000	$1,419,000
Buildings And Improvements	$18,078,000	$20,097,000	$21,998,000	$23,316,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$588,753,000	$188,912,000	$212,481,000	$119,390,000
Investments And Advances	-	$0	$7,460,000	$0
Available For Sale Securities	-	-	$7,460,000	-
Current Deferred Revenue	-	-	-	$1,700,000

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-265,998,000	$-208,364,000	$-156,420,000	$-125,501,000
Operating Activities
Operating Cash Flow	$-264,444,000	$-207,791,000	$-153,624,000	$-118,638,000
Cash Flow From Continuing Operating Activities	$-264,444,000	$-207,791,000	$-153,624,000	$-118,638,000
Operating Gains Losses	$7,181,000	-	$8,000	-
Investing Activities
Capital Expenditure	$-1,554,000	$-573,000	$-2,796,000	$-6,863,000
Investing Cash Flow	$-399,526,000	$38,276,000	$-97,824,000	$-124,718,000
Cash Flow From Continuing Investing Activities	$-399,526,000	$38,276,000	$-97,824,000	$-124,718,000
Financing Activities
Issuance Of Capital Stock	$159,323,000	$213,336,000	$161,819,000	$161,945,000
Financing Cash Flow	$878,233,000	$214,451,000	$163,536,000	$163,558,000
Cash Flow From Continuing Financing Activities	$878,233,000	$214,451,000	$163,536,000	$163,558,000
Net Other Financing Charges	$-51,518,000	-	-	-
Net Common Stock Issuance	$159,323,000	$213,336,000	$161,819,000	$161,945,000
Common Stock Issuance	$159,323,000	$213,336,000	$161,819,000	$161,945,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-54,635,000	$0	$0	-
Issuance Of Debt	$272,391,000	$0	$0	-
Interest Paid Supplemental Data	$2,015,000	$0	-	-
End Cash Position	$312,428,000	$98,165,000	$53,229,000	$141,141,000
Beginning Cash Position	$98,165,000	$53,229,000	$141,141,000	$220,939,000
Changes In Cash	$214,263,000	$44,936,000	$-87,912,000	$-79,798,000
Proceeds From Stock Option Exercised	$552,672,000	$1,115,000	$1,717,000	$1,613,000
Net Issuance Payments Of Debt	$217,756,000	$0	$0	-
Net Short Term Debt Issuance	$223,100,000	$0	$0	-
Short Term Debt Issuance	$223,100,000	$0	$0	-
Net Long Term Debt Issuance	$-5,344,000	$0	$0	-
Long Term Debt Payments	$-54,635,000	$0	$0	-
Long Term Debt Issuance	$49,291,000	$0	$0	-
Net Investment Purchase And Sale	$-397,972,000	$38,849,000	$-95,028,000	$-117,855,000
Sale Of Investment	$289,199,000	$294,452,000	$253,775,000	$60,000,000
Purchase Of Investment	$-687,171,000	$-255,603,000	$-348,803,000	$-177,855,000
Net PPE Purchase And Sale	$-1,554,000	$-573,000	$-2,796,000	$-6,863,000
Purchase Of PPE	$-1,554,000	$-573,000	$-2,796,000	$-6,863,000
Change In Working Capital	$8,011,000	$11,596,000	$11,442,000	$751,000
Change In Other Current Liabilities	$-1,532,000	$-1,386,000	$-796,000	$-8,690,000
Change In Other Current Assets	$1,561,000	$2,000	$-119,000	$-1,018,000
Change In Payables And Accrued Expense	$8,177,000	$17,314,000	$12,983,000	$11,945,000
Change In Accrued Expense	$10,686,000	$15,956,000	$8,170,000	$9,586,000
Change In Payable	$-2,509,000	$1,358,000	$4,813,000	$2,359,000
Change In Account Payable	$-2,509,000	$1,358,000	$4,813,000	$2,359,000
Change In Prepaid Assets	$-195,000	$-4,334,000	$-626,000	$-1,486,000
Other Non Cash Items	$601,000	-	$-1,700,000	$-1,360,000
Stock Based Compensation	$46,079,000	$39,740,000	$30,621,000	$18,368,000
Amortization Of Securities	$-1,962,000	$-7,619,000	$-5,173,000	$-1,638,000
Depreciation Amortization Depletion	$4,583,000	$4,351,000	$3,588,000	$5,878,000
Depreciation And Amortization	$4,583,000	$4,351,000	$3,588,000	$5,878,000
Depreciation	$4,583,000	$4,351,000	$3,588,000	$5,878,000
Gain Loss On Sale Of PPE	$0	$0	$8,000	$0
Net Income From Continuing Operations	$-328,937,000	$-255,859,000	$-192,410,000	$-140,241,000
Asset Impairment Charge	-	$0	$0	$-396,000
Sale Of PPE	-	-	-	-
Change In Receivables	-	-	-	-
Changes In Account Receivables	-	-	-	-

Fetched: 2026-06-16